MAM
ZengaTV ropes in Parle Wafers as title sponsor for India-SL series
MUMBAI: Mobile video streaming provider ZengaTV, the exclusive mobile rights for the ongoing India-Sri Lanka series, has roped in Parle Wafers as the title sponsor for the series.
Under the deal, Parle Wafers will advertise in between overs as pure FCT and also on Action Replay and Super 4‘s mirroring the traditional TV model of advertising and this alternate platform gives a choice to the brands to consider while they strategize their marketing and advertising plan.
Announcing the sponsorship, ZengaTV CEO Abhishek Joshi said, “This tie-up with Parle Wafers is an important addition to our already existing advertiser bouquet and we strongly feel is that there is enough space for every brand to advertise on the mobile TV platform and this will be very hard to ignore when they launch their future brand campaigns. Zenga TV which currently is on a very high growth trajectory is proof that this is a serious platform for the marketers to start considering.”
The series kicked off on 21 July on Ten Cricket featuring five ODIs and one Twenty20 match.
MAM
Beacon Group appoints Dr Rajesh Patel as Group CEO
36-year healthcare veteran to lead Beacon Diagnostics, Vector Biotek, Biogeny.
MUMBAI: A new chief, a fresh diagnosis and a sharper prescription for growth. Beacon Group has appointed Dr Rajesh Patel as its Group Chief Executive Officer, effective April 1, 2026, signalling a decisive push to scale its presence in the diagnostics and IVD space. Patel steps into the role with 36 years of experience across the healthcare and diagnostics industry, bringing a career shaped by leadership roles spanning sales, marketing, business development and operational strategy. His mandate is both expansive and precise: to steer the group’s overall strategic direction while tightening coordination across its three core entities Beacon Diagnostics, Vector Biotek and Biogeny Diagnostics.
In practical terms, that means driving cross-company synergies, accelerating market expansion and strengthening organisational capability areas increasingly critical as diagnostic players compete for scale in a fragmented yet rapidly evolving healthcare ecosystem. The group is positioning itself to capture unmet demand across chain laboratories, key accounts and standalone labs, segments that remain underserved despite growing diagnostic needs.
The appointment comes at a time when the In Vitro Diagnostics (IVD) sector in India is entering a more competitive and innovation-led phase, with companies focusing not just on product pipelines but also on service delivery, integration and customer-centric models. Beacon’s leadership appears to be betting that Patel’s execution-focused approach can help translate ambition into operational momentum.
Welcoming the appointment, Chairman Dr D K Joshi described Patel’s induction as a strategic move aligned with the group’s long-term vision, emphasising the role of leadership depth in navigating the next phase of growth.
For Beacon Group, the message is clear, in a sector where precision matters, leadership is the new differentiator—and this appointment is intended to set the tone for what comes next.
